Analytical Data
-
Gene name
MDR1
- Application
-
Alternative Names
MDR1；MDR1；PGY1；ATP-dependent translocase ABCB1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P13568
-
Expression Region
1084-1419aa
-
AA Sequence
KGDSENAKLSFEKYYPLMIRKSNIDVRDDGGIRINKNLIKGKVDIKDVNFRYISRPNVPIYKNLSFTCDSKKTTAIVGETGSGKSTFMNLLLRFYDLKNDHIILKNDMTNFQDYQNNNNNSLVLKNVNEFSNQSGSAEDYTVFNNNGEILLDDINICDYNLRDLRNLFSIVSQEPMLFNMSIYENIKFGREDATLEDVKRVSKFAAIDEFIESLPNKYDTNVGPYGKSLSGGQKQRIAIARALLREPKILLLDEATSSLDSNSEKLIEKTIVDIKDKADKTIITIAHRIASIKRSDKIVVFNNPDRNGTFVQSHGTHDELLSAQDGIYKKYVKLAK
-
Molecular Weight
54.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MDR1, or Multidrug Resistance Protein 1, is a crucial member of the ATP-binding cassette (ABC) transporter family, primarily responsible for the efflux of various substrates, including drugs, from cells. Its overexpression is commonly associated with multidrug resistance (MDR) in cancer cells, where it diminishes the efficacy of chemotherapeutic agents by pumping them out of the cells before they can exert their therapeutic effects. This phenomenon presents a significant challenge in cancer treatment, leading to treatment failures and poor patient outcomes. Research on MDR1 recombinant protein has gained momentum in recent years, aiming to elucidate its structural and functional characteristics, as well as its role in drug transport mechanisms. Investigators are focusing on the production of recombinant MDR1 proteins to study their interactions with substrates and inhibitors, which can help in designing effective strategies to overcome drug resistance. Furthermore, the study of MDR1 is critical for improving drug formulation and delivery systems, thereby enhancing the therapeutic index of various anticancer drugs. Understanding the molecular basis behind MDR1-mediated drug resistance may also pave the way for novel therapeutic interventions, including the development of MDR1 inhibitors or the use of nanocarriers that bypass the efflux mechanisms. Overall, MADR1 recombinant protein research is vital for advancing our knowledge of multidrug resistance and improving outcomes in cancer therapy.
